News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Holding AG Says Herceptin with Chemo Prolongs Survival
May 30, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Roche Holding AG's Herceptin, when added to chemotherapy Xeloda, prolonged survival without progression of breast cancer by three months compared to chemotherapy alone, the Swiss drugmaker said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
MORE ON THIS TOPIC
Friedreich’s ataxia
Larimar’s Friedreich’s Ataxia Drug Troubled by Anaphylaxis Concerns; Shares Fall
September 30, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
New Confirmatory Study Hints at ‘Alignment’ Between Applied Therapeutics, FDA for Rare Disease Drug
September 29, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Hansa Kidney Transplant Drug Aces Phase III Study, Headed to FDA
September 26, 2025
·
2 min read
·
Tristan Manalac
Job Trends
$100,000 H-1B Fee Leaves Biopharma Grappling With Impact
September 25, 2025
·
6 min read
·
Angela Gabriel
